VGF Expression by Monocytes in Patients with Alzheimer's Disease and Vascular Dementia

1Citations
Citations of this article
11Readers
Mendeley users who have this article in their library.
Get full text

Abstract

Because its secretion is changed in cerebrospinal fluid and peripheral blood, the neuronal polypeptide VGF (nonacronymic) has been discussed as a biomarker for neuropsychiatric disorders. We have shown an enhanced VGF expression by T-cells from Alzheimer s disease (AD) patients. In this study, we investigated the VGF expression by peripheral monocytes in 38 AD patients, 5 patients with vascular dementia (VD), and 20 neuropsychiatrically healthy individuals using flow cytometry. We determined an enhanced number of VGF-expressing monocytes in VD patients compared to AD patients. VGF+CD14+ monocytes were not correlated with age, body mass index, Mini-Mental State Examination (MMSE), or Q albumin. These preliminary data support findings indicating that VGF might play a role as a peripheral biomarker in VD.

Cite

CITATION STYLE

APA

Busse, S., Meyer, E., Dobrowolny, H., Mawrin, C., Hartig, R., Bogerts, B., & Busse, M. (2022). VGF Expression by Monocytes in Patients with Alzheimer’s Disease and Vascular Dementia. GeroPsych: The Journal of Gerontopsychology and Geriatric Psychiatry, 35(3), 149–155. https://doi.org/10.1024/1662-9647/a000263

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Save time finding and organizing research with Mendeley

Sign up for free